Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
| Revenue (TTM) | $596.96M |
| Gross Profit (TTM) | $501.66M |
| EBITDA | $305.83M |
| Operating Margin | 49.00% |
| Return on Equity | 24.50% |
| Return on Assets | 16.30% |
| Revenue/Share (TTM) | $4.87 |
| Book Value | $8.29 |
| Price-to-Book | 3.81 |
| Price-to-Sales (TTM) | 6.45 |
| EV/Revenue | 5.2 |
| EV/EBITDA | 10.15 |
| Quarterly Earnings Growth (YoY) | 11.10% |
| Quarterly Revenue Growth (YoY) | 5.60% |
| Shares Outstanding | $122.42M |
| Float | $115.58M |
| % Insiders | 5.57% |
| % Institutions | 89.70% |
Volatility is currently expanding
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led t.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) related to its sale to Angelini Pharma S.p.A. Under the terms of the proposed transaction Catalyst shareholders are expected to receive $31.50 per share in cash. Is it a fair deal?
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash.Halper Sadeh encourages Catalyst shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Catalyst and its board of dir.
